ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.
TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.
Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.
Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.
Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity, translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor. To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage. Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use. Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.
TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity, translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor. To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage. Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use. Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.
AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.
Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity, translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor. To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage. Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use. Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity, translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor. To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage. Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use. Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.
Evolva is a biotechnology company based in Reinach, Switzerland, founded in 2004. The company specializes in the research, development, and commercialization of nature-based ingredients that are ready for formulation. Utilizing a proprietary synthetic biology platform, Evolva creates innovative small-molecule compounds that replicate the beneficial properties of natural products while mitigating their disadvantages. Their offerings find applications in various sectors, including flavors and fragrances, health ingredients, and health protection. Through its advanced technology, Evolva aims to provide high-quality ingredients that meet the needs of diverse industries.
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Evolva is a biotechnology company based in Reinach, Switzerland, founded in 2004. The company specializes in the research, development, and commercialization of nature-based ingredients that are ready for formulation. Utilizing a proprietary synthetic biology platform, Evolva creates innovative small-molecule compounds that replicate the beneficial properties of natural products while mitigating their disadvantages. Their offerings find applications in various sectors, including flavors and fragrances, health ingredients, and health protection. Through its advanced technology, Evolva aims to provide high-quality ingredients that meet the needs of diverse industries.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Lumavita is an independent, specialty biopharmaceutical company focused on global development and commercialisation of novel anti-infectives for women’s health. Lumavita is based in Basel, Switzerland, home to a significant and growing biopharmaceutical sector.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
Idiag is a specialist in interfacing research & development with sales and marketing. A central business aim is to convert innovative ideas on medical technology into products ready to market. Therefore Idiag offers to Universities and Innovation Centres, to take over final development, production and marketing for their unused medical product potential. Furthermore Idiag offers to manufacturer of high quality supplementing products, to act as reseller. Idiag then uses its existing resources, networks and excellence for market penetration and sales, within Switzerland and Germany.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases. These conditions represent areas of high unmet medical need, often involving orphan and niche indications that currently lack effective therapies. The company focuses on various therapeutic segments, including neuro-ophthalmological, pulmonary, and neuromuscular diseases. Santhera primarily generates its revenue from the European Union, aiming to address significant health challenges faced by patients with these rare disorders.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
EyeSense AG specializes in the development of ophthalmic diagnostic systems aimed at improving glucose testing for diabetic patients. The company focuses on creating innovative, pain-free blood glucose monitoring devices that facilitate better diabetes management. By utilizing advanced fiber optic sensors, EyeSense AG's technology enables continuous blood sugar measurement, thereby enhancing the therapy and care available to individuals with diabetes.
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Spinal Cord Therapeutics GmbH
Series A in 2005
Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.
Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.
4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.
CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
Thommen Medical is a medical device company focused on the development, production, and sale of dental implants under the brand name SPI (Swiss Precision Implant). The company emphasizes innovation and design excellence in its implant systems, which are crafted to enhance patient comfort during surgery and ensure long-term stability. In addition to dental implants, Thommen Medical also offers biomaterial solutions for bone and tissue regeneration. The company's products are developed in collaboration with leading scientific and dental clinicians, ensuring precision and ease of use in their applications.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.